Signal Suppression of Normal Liver Tissue by Phase Corrected Inversion Recovery

1989 ◽  
Vol 13 (4) ◽  
pp. 650-655 ◽  
Author(s):  
Bernt Lehmann ◽  
Ezio Fanucci ◽  
Francesco Gigli ◽  
Detlev Uhlenbrock ◽  
Carlo Bartolozzi
2020 ◽  
Vol 3 (1) ◽  
pp. 1
Author(s):  
Eerdunbagena Ning ◽  
Zhijun Wang

Objective: To assess the safety, feasibility and eluting efficiency of intrahepatic arterial delivery of sorafenib on normal liver tissue of rabbit. Methods: 24 New Zealand rabbits were randomly divided into three groups: group Ⅰ (Lipiodol-sorafenid), group Ⅱ (Lipiodol) and group Ⅲ (Sorafenib). Group Ⅰ and Ⅱ were treated by transcatheter selective hepatic arterial embolization with emulsions of lipiodol and sorafenib or with only lipiodol, while group Ⅲ was given hepatic arterial infusion with sorafenib. Sorafenib concentration in plasma was determined by HPLC (high performance liquid chromatography) in 0 min, 20 min, 1h, 2h, 4h, 8h, 16h, 32h and 48h respectively. The breathing rate, heart rate, rectal temperature and body weight were measured, as well the blood routine test and the function of liver, kidney, and heart. Two animals of each group were respectively killed in the 3rd day, 1st, 3rd and 6th week after treatment. Histopathologic study was done to liver, heart, kinney, lung, brain, gall bladder and intestine. Result: ① The peak sorafenib concentration (Cmax)and AUC(Area under curve) in plasma in groupⅠwas 2.46±0.101μg/ml and 945.72 ± 52.3 μg/mL.min respectively, while in group Ⅲ which was 3.78±0.180 ug/ml and 546.98±21.1μg/mL.min. Compared with groupⅢ, the Cmax and AUC of groupⅠhad a significant statistics difference (p<0.05). ② The breathing rate, heart rate, rectal temperature and AST/ALT,WBC,NEU% of group Ⅰand groupⅢhas a significant statistics difference(p<0.05) in the 3rd day. ③CK ,CK-MB, DB, Cr,BUN,RBC,PLT in plasma did not change in all group.④Local necrosis was seen in group Ⅰand group Ⅱin the 3rd day and 1st week, but they did not seem to be different. Group Ⅲ showed no necrosis. Granulation tissue with bile duty, portal vein and microfossils hyperplasia were seen in local necrosis area in the 3rd week. No pathological changes were found in brain, heart, kidney, intestine and gallbladder. Conclusion: TAE with emulsions of lipiodol and sorafenib is feasible, safe and has some slow-release effect.


2018 ◽  
Vol 36 (9) ◽  
pp. 559-565 ◽  
Author(s):  
Nobuyoshi Fukumitsu ◽  
Shinsei Takahashi ◽  
Toshiyuki Okumura ◽  
Toshiki Ishida ◽  
Keiko Nemoto Murofushi ◽  
...  

2010 ◽  
Vol 38 (7) ◽  
pp. 4359-4367 ◽  
Author(s):  
Tie-Jun Wang ◽  
Zhong-Shan Liu ◽  
Zhao-Chong Zeng ◽  
Shi-Suo Du ◽  
Ming Qiang ◽  
...  

2017 ◽  
Vol 20 (1) ◽  
pp. 51-56
Author(s):  
K. Glińska-Suchocka ◽  
K. Kubiak ◽  
J. Spużak ◽  
M. Jankowski ◽  
P. Borusewicz

Abstract Shear wave elastography is a novel technique enabling real-time measurement of the elasticity of liver tissue. The color map is superimposed on the classic ultrasound image of the assessed tissue, which enables a precise evaluation of the stiffness of the liver tissue. The aim of the study was to assess the stiffness of normal liver tissue in the guinea pig using shear wave elastography. The study was carried out on 36 guinea pigs using the SuperSonic Imagine Aixplorer scanner, and a 1 to 6 MH convex SC6-1 transducer. An ultrasound guided Try-Cut liver core needle biopsy was carried out in all the studied animals and the collected samples were examined to exclude pathological lesions. The mean liver tissue stiffness ranged from 0.89 to 5.40 kPa. We found that shear wave elastography is an easy, non-invasive technique that can be used to assess the stiffness of liver tissue. The obtained results can be used in future studies to assess the types and changes of liver tissue in the course of various types of liver disease.


1994 ◽  
Vol 201 (2) ◽  
pp. 559-566 ◽  
Author(s):  
E.A. Roberts ◽  
K.N. Furuya ◽  
B.K. Tang ◽  
W. Kalow

Hepatology ◽  
2017 ◽  
Vol 65 (4) ◽  
pp. 1384-1392 ◽  
Author(s):  
George K. Michalopoulos

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15759-e15759
Author(s):  
Venessa T. Chin ◽  
Adnan Nagrial ◽  
James Conway ◽  
Claire Vennin ◽  
Lorraine A. Chantrill ◽  
...  

e15759 Background: PC is a highly lethal disease which metastasises early. The sequencing efforts of the Australian Pancreatic Cancer Genome Initiative (APGI) identified ROCK-1 as a target of interest. The Rho/ROCK pathway is essential in cellular movement, metastasis, vasculogenesis and stromal signaling. Fasudil (F) is a ROCK inhibitor which has been shown to be safe for human use. Using unique, patient derived models, we have previously shown that F plus gemcitabine (G) does not reduce cellular proliferation in vitro but reduces tumour size and improves overall survival (OS) in subcutaneous patient-derived xenografts (PDX). However, PDXs are critisised for not fully recapitulating the human condition. Here we aimed to generate a patient-derived orthotopic xenograft (O-PDX) which could be used to assess the effects of F + G on metastasis formation and OS. Methods: One patient-derived cell line (PDCL) was labled with firefly luciferase. This was injected into the pancreas of NOD/Shi- scid/IL-2Rγnull (NSG) mice to generate the O-PDX model. The O-PDX was imaged weekly with the IVIS imaging system. The O-PDXs were treated with saline control (S) (n = 8), gemcitabine (G) (n = 10) fasudil (F) (n = 6) or gemcitabine + fasudil (GF) (n = 10). Mice were culled once radiographic or clinical evidence of ascites was detected. Metastasis free (MFS) and OS were recorded. Vessel quantification was performed via CD-31 staining. Results: Metastases seen (spleen, liver, lung, ovary) on imaging were confirmed using GFP stains on immunohistochemistry. F prolonged MFS but not OS when compared with S. GF significantly prolonged MFS (33.5 versus 43 days; p = 0.0339) and OS (51.5 versus 64 days; p = 0.0035). CD-31 staining showed that treatment with F resulted in increased vascularity in the liver metastases and normal liver tissue but not in the pancreas tumour. Conclusions: The addition of Fasudil to gemcitabine improves MFS and OS in an orthotopic model of PC and is a promising new therapeutic option. The increase in vascularity of the metastases and normal liver tissue suggest that changes in vascularity are important and may result in improved delivery of gemcitabine.


2021 ◽  
pp. 181-194
Author(s):  
Ashirbad Nanda ◽  
Chinmaya Chidananda Behera ◽  
Dilip Kumar Patel ◽  
Vikas Kumar ◽  
Bhisma N Ratha ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document